Lilly: Seeking Solutions to a Global MDR-TB Crisis

Over a decade ago, we committed ourselves to the global fight against multi-drug resistant tuberculosis (MDR-TB). Today, a new report out from the Lilly MDR-TB Partnership shares insights from a core component of the partnership: the technology transfer program. The process began when independent researchers identified two Lilly-manufactured medicines as effective treatments for MDR-TB.    Equipped with that knowledge, we endeavored to set-up a novel solution to combat the global rise of the disease. To create a reliable and sustainable supply of these two medicines, we transferred our trademarks, manufacturing technology, and knowledge to manufacturers in the most affected countries. The new report seeks to tell that story and share lessons learned.   Read on for an infographic that highlights important milestones in the Lilly MDR-TB Partnership technology transfer program.